首页|乳癌新辅助化疗后Ki-67变化与临床疗效的关系

乳癌新辅助化疗后Ki-67变化与临床疗效的关系

扫码查看
目的 探讨乳癌病人新辅助化疗后Ki-67的表达变化与临床疗效的关系.方法 选取Ⅱ~Ⅲ期的女性乳癌病人112例,术前均接受新辅助化疗.采用万科真空辅助旋切系统取样,应用免疫组化法检测新辅助化疗前后Ki-67的表达,分析其表达变化与临床疗效的关系.结果 乳癌病人新辅助化疗前Ki-67的高表达率为80.4%,低表达率为19.6%;新辅助化疗后Ki-67的高表达率为26.8%,低表达率为73.2%,新辅助化疗前后Ki-67的表达比较差异有统计学意义(x2=64.62,P<0.05).新辅助化疗的临床有效率为45.5%,临床获益率为84.8%.Ki-67高表达的病人对新辅助化疗敏感性较高,化疗后Ki-67的表达由高转为低的病人临床疗效较好,化疗后Ki-67的表达没有变化或者由低转为高的病人临床疗效较差,Ki-67的表达变化与临床疗效有关(x 2=25.153,P<0.05).结论 Ki-67表达很可能成为评估乳癌新辅助化疗效果的生物学指标,对化疗预后有提示作用.
RELATIONSHIP BETWEEN KI-67 EXPRESSION AND CLINICAL OUTCOME IN BREAST CANCER AFTER NEOADJUVANT CHEMOTHERAPY
Objective To investigate the association of expression of Ki-67 with clinical effectiveness in breast cancer after neoadjuvant chemotherapy (NC).Methods One hundred and twelve female patients with stage Ⅱ-Ⅲ breast cancer were selected,and given a neoadjuvant chemotherapy before surgery.Samples were taken using EnCor vacuum assisted biopsy instrument,the expression of Ki-67-before and after NC-was detected employing immunohistochemistry,the association of Ki-67 with clinical efficacy was analyzed.Results Before NC,the high expression rate of Ki-67 was 80.4%,and the low of that was 19.6%;after NC,the high expression of Ki-67 was 26.8%,and the low of that was 73.2%,the differences in Ki-67 expression rates-before and after NC-were statistically significant (x2 =64.62,P<0.05).The clinical effective rate for NC was 45.5%,and the clinical benefit rate was 84.8%.Patients with high expression of Ki-67 were sensitive to NC,and the clinical efficacy was better in those with decline of Ki-67 after NC,and the efficacy was poor for those with no changes of Ki 67 after NC or Ki-67 raised from low to high,the changes of Ki-67 expression were related to clinical effectiveness (x2=25.153,P<0.05).Conclusion Ki-67 is likely to become a bioindicator in evaluation of neoadjuvant chemotherapy in breast cancer,which can predict the prognosis of the cancer after this kind of treatment.

breast neoplasmschemoradiotherapy, adjuvantKi-67 antigentreatment outcome

李文金

展开 >

临沂市肿瘤医院乳腺二科,山东临沂276001

乳房肿瘤 放化疗,辅助 Ki-67抗原 治疗结果

2017

齐鲁医学杂志
青岛大学医学院

齐鲁医学杂志

影响因子:0.609
ISSN:1008-0341
年,卷(期):2017.32(1)
  • 1
  • 2